Lukewarm data for Second Sight
Second Sight’s second product might lead the company to second place in the market.
Aldeyra seeks to Alleviate worries with conjunctivitis win
Pivotal data validate Aldeyra’s lead project, reproxalap, but there are questions about a lack of dose response.
Upcoming events – Roche aims to change autism and Ocular awaits pivotal results
Roche awaits a high-risk, high-reward readout in autism, while for Ocular Therapeutix placebo ought to be easier to beat than active control.
Nightstar gives Biogen a cheap way to expand in gene therapy
Biogen’s $877m buyout of Nightstar Therapeutics provides yet more evidence that gene therapy is reaching critical mass.
Reneuron eyes a partner with new stem cell data
Promising retinitis pigmentosa results have given Reneuron a boost, but the company still faces a pivotal trial.
Johnson & Johnson dips a toe into gene therapy
A deal between J&J and Meiragtx in eye disease shows growing interest from big pharma as gene therapy's commercial issues come into focus.
Aurinia sees another way forward for voclosporin
Aurinia's lead project shows promise in its back-up use of dry eye, but risks distracting the company from a late-stage lupus trial.
Upcoming events – Data for Axsome's combo in depression and Aldeyra in allergic conjunctivitis
Two readouts are approaching for Axsome's AXS-05, and Aldeyra is facing a data-heavy 2019.
Clearside’s future clouds over
After failing in retinal vein occlusion, the prospects for the eye project Xipere – and Clearside Biomedical itself – hinge on the smaller uveitis indication.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.